Editorial

Coulston, F.; Kolbye, Albert C.; Carr, C. Jelleff

doi:10.1016/s0273-2300(05)80058-3

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The critical need to assess the potential allergenicity of the novel proteins in genetically engineered foods may not have been appreciated in the early days of agricultural biotechnology [20]. However, the US Food and Drug Administration and other regulatory agencies recognized this potential risk in the early 1990s [21].…”

Section: Historical Development Of the Allergenicity Assessment Of Gementioning

confidence: 99%

Review of the development of methodology for evaluating the human allergenic potential of novel proteins

Taylor¹

2006

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Safety assessment of novel proteins in genetic-engineered foods is a key component of the overall safety evaluation for these products. Since allergens are typically proteins, assessment of the potential allergenicity of the novel proteins in genetically engineered foods is critical. This article reviews methods available to assess the potential allergenicity of novel proteins, as well as problems and deficiencies in the existing methods. The role of bioinformatics and knowledge of allergenic epitopes in developing new approaches to this problem is discussed.

show abstract

Section: Historical Development Of the Allergenicity Assessment Of Gementioning

confidence: 99%

Review of the development of methodology for evaluating the human allergenic potential of novel proteins

Taylor¹

2006

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

Assessment of the food safety issues related to genetically modified foods

et al. 2001

View full text Add to dashboard Cite

SummaryInternational consensus has been reached on the principles regarding evaluation of the food safety of genetically modi®ed plants. The concept of substantial equivalence has been developed as part of a safety evaluation framework, based on the idea that existing foods can serve as a basis for comparing the properties of genetically modi®ed foods with the appropriate counterpart. Application of the concept is not a safety assessment per se, but helps to identify similarities and differences between the existing food and the new product, which are then subject to further toxicological investigation. Substantial equivalence is a starting point in the safety evaluation, rather than an endpoint of the assessment. Consensus on practical application of the principle should be further elaborated. Experiences with the safety testing of newly inserted proteins and of whole genetically modi®ed foods are reviewed, and limitations of current test methodologies are discussed. The development and validation of new pro®ling methods such as DNA microarray technology, proteomics, and metabolomics for the identi®cation and characterization of unintended effects, which may occur as a result of the genetic modi®cation, is recommended. The assessment of the allergenicity of newly inserted proteins and of marker genes is discussed. An issue that will gain importance in the near future is that of postmarketing surveillance of the foods derived from genetically modi®ed crops. It is concluded, among others that, that application of the principle of substantial equivalence has proven adequate, and that no alternative adequate safety assessment strategies are available.

show abstract

Commercialization of genetically engineered crops

Horsch

1993

Phil. Trans. R. Soc. Lond. B

View full text Add to dashboard Cite

More abundant harvests from insect- and disease-resistant crops, vine-ripened tomatoes, or less oily potato chips or french fries are some of the benefits that will result from single gene improvements under development today. These single gene traits will be combined with the best new varieties produced by traditional plant breeding and will accelerate the pace and the scope of our ability to develop even better and more productive crops in the future. The initial group of genetic improvements were first field tested in 1987, improved upon over the past 6 years, and are finally approaching the first commercial sales over the next 3 to 4 years. The key hurdles from discovery of a promising lead to a commercial product trait include: (i) gene cloning and expression; (ii) product development; (iii) field testing; (iv) breeding into multiple elite varieties; (v) product characterization and regulatory review; (vi) public acceptance; and (vii) marketing. The expense and risk to bring transformed crops to market successfully is significantly higher than for traditionally developed new varieties. The high value of some single gene targets and the possibility for patent protection of the processes and final products provide the incentive for private investment in this area. The value to farmers, consumers, the environment and society in general is very high because the problems being solved are those that have resisted previous attempts through conventional means. Public investment in basic plant science research and private investment in product development is a powerful combination for continual improvement in lowering the cost and improving the quality of the world's food supply.

show abstract

Editorial

Cited by 5 publications

References 0 publications

Review of the development of methodology for evaluating the human allergenic potential of novel proteins

Review of the development of methodology for evaluating the human allergenic potential of novel proteins

Assessment of the food safety issues related to genetically modified foods

Commercialization of genetically engineered crops

Contact Info

Product

Resources

About